ATARA BIOTHERAPEUTICS, INC. Payments for Restructuring
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Payments for Restructuring of $871.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. payments for restructuring for the quarter ending 2026-06-30 was $125.00K, a 97.65% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments for restructuring for the quarter ending 2026-03-31 was $746.00K, a 64.89% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments for restructuring for the quarter ending 2025-12-31 was $969.00K, a 587.23% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments for restructuring for the quarter ending 2025-09-30 was $1.66M, a 166.35% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments for restructuring for fiscal 2025 was $10.08M, a 8.42% increase from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. payments for restructuring for fiscal 2024 was $9.30M, a 177.39% increase from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. payments for restructuring for fiscal 2023 was $3.35M, a 24.15% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. payments for restructuring for fiscal 2022 was $4.42M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2026-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $871.00K 10-Q · filed 2026-08-12 | $1.84M derived: sum of 3 quarters · filed 2026-08-12 | $3.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $746.00K 10-Q · filed 2026-05-12 | $1.72M derived: sum of 2 quarters · filed 2026-05-12 | $3.38M derived: sum of 3 quarters · filed 2026-05-12 | $8.70M derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $969.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.63M derived: sum of 2 quarters · filed 2026-03-16 | $7.96M derived: sum of 3 quarters · filed 2026-03-16 | $10.08M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.99M derived: sum of 2 quarters · filed 2025-11-12 | $9.11M 10-Q · filed 2025-11-12 | $9.25M derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | $5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $7.45M 10-Q · filed 2025-08-11 | $7.59M derived: sum of 3 quarters · filed 2026-03-16 | $8.21M derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | $2.13M 10-Q · filed 2025-05-15 | $2.27M derived: sum of 2 quarters · filed 2026-03-16 | $2.89M derived: sum of 3 quarters · filed 2026-03-16 | $4.78M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $765.00K derived: sum of 2 quarters · filed 2026-03-16 | $2.66M derived: sum of 3 quarters · filed 2026-03-16 | $9.30M 10-K · filed 2026-03-16 |
| 2024-09-30 | $624.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.52M derived: sum of 2 quarters · filed 2024-11-12 | $9.16M 10-Q · filed 2024-11-12 | $11.00M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $8.53M 10-Q · filed 2024-08-12 | $10.37M derived: sum of 3 quarters · filed 2025-03-07 | $10.80M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-03-31 | $6.64M 10-Q · filed 2024-05-09 | $8.48M derived: sum of 2 quarters · filed 2025-03-07 | $8.91M derived: sum of 3 quarters · filed 2025-03-07 | $9.14M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $2.27M derived: sum of 2 quarters · filed 2025-03-07 | $2.50M derived: sum of 3 quarters · filed 2025-03-07 | $3.35M 10-K · filed 2025-03-07 |
| 2023-09-30 | $429.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $661.00K derived: sum of 2 quarters · filed 2023-11-01 | $1.51M 10-Q · filed 2023-11-01 | $4.13M derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.08M 10-Q · filed 2023-08-08 | $3.70M derived: sum of 3 quarters · filed 2024-03-28 | |
| 2023-03-31 | $852.00K 10-Q · filed 2023-05-08 | $3.46M derived: sum of 2 quarters · filed 2024-03-28 | ||
| 2022-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $4.42M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $1.81M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |